These press releases are for business and financial media.
-
-
- Press release archive 2008
- 08 May 2008
- AstraZeneca Submits sNDA for Seroquel XR™ for the Treatment of Generalised Anxiety Disorder – a First for the Atypical Antipsychotic Class of Medicines AstraZeneca today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of generalised anxiety disorder (GAD), including maintenance of antianxiety effect. It is the first time approval has been sought for an atypical antipsychotic medicine in GAD.
-
-
-
- Press release archive 2008
- 06 May 2008
- EPO Announces Symbicort® European COPD Use Patent Decision AstraZeneca today announced that the European Patent Office (EPO) Technical Board of Appeal has made a final ruling that the European Combination patent covering the use of Symbicort® (formoterol and budesonide) for the treatment of chronic obstructive pulmonary disease (COPD) (EPB1014993) has been revoked, following an appeal from generic manufacturers Norton Healthcare and Generics UK.
-
-
-
- Press release archive 2008
- 02 May 2008
- AstraZeneca Files Marketing Application in Europe for EGFR Inhibitor Gefitinib (IRESSA™) in Locally Advanced Pre-Treated Non-Small Cell Lung Cancer AstraZeneca today announced the submission of a marketing authorisation application to the European Medicines Agency (EMEA) for its oral anti-cancer drug, gefitinib (IRESSA™) as a treatment for locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have been pre-treated with platinum-containing chemotherapy.
-
-
-
- Press release archive 2008
- 30 April 2008
- AstraZeneca Submits sNDA for SYMBICORT® for COPD Treatment AstraZeneca today announced submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) to seek approval of a new indication for SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). SYMBICORT is currently approved for the long-term maintenance treatment of asthma in patients 12 years and older.
-
-
-
- Press release archive 2008
- 24 April 2008
- AstraZeneca PLC First Quarter Results 2008 "Underlying business performance on track to achieve full year financial targets. Core EPS target increased to reflect year to date currency impact."
-
-
-
- Press release archive 2008
- 15 April 2008
- AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy AstraZeneca today announced it has entered into a settlement agreement in its Nexium patent infringement litigation against Ranbaxy Laboratories Ltd. and its affiliates (“Ranbaxy”).
-
-
-
- Press release archive 2008
- 31 March 2008
- Crestor Outcomes Study JUPITER Closes Early Due To Unequivocal Evidence Of Benefit AstraZeneca today announced it has decided to stop the CRESTOR JUPITER clinical study early based on a recommendation from an Independent Data Monitoring Board and the JUPITER Steering Committee, which met on March 29, 2008. The study will be stopped early because there is unequivocal evidence of a reduction in cardiovascular morbidity and mortality amongst patients who received CRESTOR when compared to placebo.
-
-
-
- Press release archive 2008
- 13 March 2008
- AstraZeneca and Silence Therapeutics To Collaborate On Novel Approaches For siRNA Drug Delivery AstraZeneca today announced a collaboration with Silence Therapeutics plc, focused on the development of a range of novel approaches for the delivery of short interfering ribonucleic acid (siRNA) molecules. The deal builds on Silence Therapeutics’ expertise in the delivery of siRNA molecules, in particular its success with the functional systemic delivery of siRNA in vivo using its proprietary AtuPLEX technology. The financial details of this collaboration, in which both parties will contribute expertise,
-
-
-
- Press release archive 2008
- 12 March 2008
- Trial Date Set For SEROQUEL® Patent Litigation AstraZeneca today announced a trial date has been set for patent litigation in the US District Court for the District of New Jersey against Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca’s patent as a result of Teva’s and Sandoz’s filings of Abbreviated New Drug Applications (ANDAs). The ANDAs seek approval to market generic versions of SEROQUEL® (quetiapine fumarate tablets) in the US before SEROQUEL’s patent expires in 2011. The Court has set a date for
-
-
-
- Press release archive 2008
- 11 March 2008
- Clinical Oncology Publishes Findings from First-Ever Initiative on Sustainable Breast Cancer Treatment in the Developing World In response to the growing burden of cancer in the developing world, AstraZeneca, in partnership with Tikur Anbessa Hospital, Addis Ababa, The Ethiopian Ministry of Health and AXIOS, developed a framework two years ago for the first-ever programme to raise awareness, diagnose and treat breast cancer in Ethiopia. The interim results of this five-year initiative are reported in the March edition of Clinical Oncology *.
-
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 09:18 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
